- Home
- IOBT vs PLRX Comparison
IOBT vs PLRX Comparison
Compare IOBT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- PLRX
- Stock Information
- Founded
- IOBT 2014
- PLRX 2015
- Country
- IOBT Denmark
- PLRX United States
- Employees
- IOBT N/A
- PLRX N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- PLRX Health Care
- Exchange
- IOBT Nasdaq
- PLRX Nasdaq
- Market Cap
- IOBT 99.5M
- PLRX 84.7M
- IPO Year
- IOBT 2021
- PLRX 2020
- Fundamental
- Price
- IOBT $1.48
- PLRX $1.29
- Analyst Decision
- IOBT Strong Buy
- PLRX Hold
- Analyst Count
- IOBT 3
- PLRX 10
- Target Price
- IOBT $9.33
- PLRX $9.79
- AVG Volume (30 Days)
- IOBT 155.1K
- PLRX 1.5M
- Earning Date
- IOBT 08-12-2025
- PLRX 08-06-2025
- Dividend Yield
- IOBT N/A
- PLRX N/A
- EPS Growth
- IOBT N/A
- PLRX N/A
- EPS
- IOBT N/A
- PLRX N/A
- Revenue
- IOBT N/A
- PLRX N/A
- Revenue This Year
- IOBT N/A
- PLRX N/A
- Revenue Next Year
- IOBT N/A
- PLRX N/A
- P/E Ratio
- IOBT N/A
- PLRX N/A
- Revenue Growth
- IOBT N/A
- PLRX N/A
- 52 Week Low
- IOBT $0.66
- PLRX $1.10
- 52 Week High
- IOBT $1.73
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- IOBT 59.40
- PLRX 43.30
- Support Level
- IOBT $1.30
- PLRX $1.13
- Resistance Level
- IOBT $1.55
- PLRX $1.43
- Average True Range (ATR)
- IOBT 0.11
- PLRX 0.11
- MACD
- IOBT -0.01
- PLRX -0.01
- Stochastic Oscillator
- IOBT 82.86
- PLRX 37.57
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.